Clinical Trial Update: Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of tanespimycin and bortezomib in adults with advanced solid tumors or lymphomas; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Malt
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma | Phase 1 | Status: TERMINATED